Faheem Hasnain acknowledges another setback for the Gossamer pipeline, but investors aren't panicking
Faheem Hasnain’s attempt to break new ground in treating ulcerative colitis at Gossamer Bio has broken down at the Phase II finish line.
The biotech CEO — best known for selling Receptos to Celgene for $7.2 billion on the promise of ozanimod — put out word Monday morning that their mid-stage study for GB004 in UC was a complete flop, failing the primary and secondary endpoints and forcing the end of the extension portions of the SHIFT-UC study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.